Relitegatide
Relitegatide is a selective αvβ6 integrin-binding peptide. Relitegatide functions as the αvβ6-binding building block of the trimeric PET probe Trivehexin. Relitegatide can be used for research on pancreatic ductal adenocarcinoma (PDAC).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2708163-13-5
- Formule: C51H75N13O13
- Masse moléculaire:1078.22
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform Radionuclide-Drug Conjugates (RDCs)
More
Activité biologique
Description
IC50 & Target
[1]|
αvβ6 |
RDC Peptide |
Chemical Information
-
CAS No. 2708163-13-5
-
Masse moléculaire 1078.22
-
Formule C51H75N13O13
-
Sequence
c[Tyr-Arg-Gly-Asp-Leu-Ala-Tyr-DPro-(NMe)Lys]
-
Sequence Shortening
c[YRGDLAY-DPro-(NMe)K]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Quigley NG, et al. PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" αvβ6 with Ga-68-Trivehexin. Eur J Nucl Med Mol Imaging. 2022;49(4):1136-1147. [Content Brief]
[2]. Zhang X, et al. Design, Synthesis, and Biological Evaluation of [18F]AlF-Labeled Integrin αvβ6-Targeting Tracers for Pancreatic Cancer Imaging. J Med Chem. 2025 Jul 10;68(13):14028-14040. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)